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ABSTRACT
Background: The treatment of patients with multiple synchronous tumors is 
challenging and complex. The use of next generation sequencing (NGS) may help in 
identification of germline mutations in genes involved in a common etiology for both 
tumors thus allowing a common effective therapeutic strategy. Patients and Methods: 
We describe the unexpected positive results obtained in a young woman with relapsed 
chemo-resistant stage IVB cervical and synchronous stage IV lung cancer, who 
underwent an interdisciplinary approach including palliative surgery with laparoscopic 
total pelvic exenteratio followed by a chemo-immunotherapy protocol with the anti-
Programmed Death (PD)-1 antibody nivolumab plus metronomic cyclophosphamide. 
The treatment choice was based on tumor PD-Ligand 1 assessment and NGS analysis 
for the identification of potential treatment targets. Outcomes included tumor objective 
response and patient-centered outcomes (pain, performance status and overall quality 
of life). Results: Laparoscopic surgery obtained an immediate symptom control and 
allowed the early start of medical treatment. One month after combined therapy start 
the patient achieved a significant improvement in performance status, pain, overall 
Quality of life and after 3 months she resumed working. After 3 and 6 months of 
treatment we observed an objective dimensional and metabolic response. Currently, 
after 24 months (and 48 cycles of nivolumab) the patient is continuing to benefit 
from treatment: she is in complete remission, with good performance status and she 
is working and leading a self-dependent life. Conclusion: Our study strongly affirms 
the efficacy of an interdisciplinary approach including surgical and innovative medical 
strategies based on immunotherapy in patients with advanced chemo-resistant 
synchronous cervical and lung cancer. The present findings support the use of NGS to 
drive a targeted rational treatment especially in heavily pre-treated patients.
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INTRODUCTION
Multiple primary tumors that develop in different 
organs are called synchronous when they are diagnosed 
within a period of <6 months (IARC definition) or 2 
months (SEER database) [1]. Synchronous cancers of 
the cervix and lung are rarely reported [2]; however, 
a significantly higher incidence of a secondary lung 
malignancy has been reported in patients with cervical 
cancer [3, 4], suggesting an abnormal genetic background 
and/or a common etiology for both tumors. Some studies 
have suggested that both cervical and lung cancers may 
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be related to the socioeconomic status and some lifestyle-
related risk factors such as smoking. The therapy of 
patients with multiple synchronous tumors is demanding 
and frequently a dilemma [1]. The main difficulty is to 
establish a therapeutic approach that deals with both 
cancers without increasing toxicity or pharmacological 
interactions and has no detrimental effects on the 
final clinical outcome. While surgery or radiation/
chemoradiation therapy can cover both malignancies in the 
case of localized disease, it is often difficult to choose an 
optimal regimen in advanced disease. Treatment strategies 
may be based on the prognosis of both tumors, and today 
on their molecular profile and genetic background, 
availability of an active systemic regimen for both cancers, 
and the choice between a radical or palliative approach. 
Then, the identification by the modern next 
generation sequencing (NGS) analysis of germline 
mutations in genes involved in a common etiology 
for both tumors may facilitate a common effective 
therapeutic strategy in patients with synchronous cancers. 
Moreover, the use of NGS may be fundamental to identify 
predictive biomarkers of response/resistance to systemic 
chemotherapy and immune checkpoint inhibitors, as 
a prelude to the development of a rational treatment 
strategy, especially in pre-treated patients [5]. In particular, 
effective treatment in advanced cervical cancer after first-
line chemotherapy is not established. In the last years 
the use of immunotherapy with anti-programmed death 
(PD)-1 antibody demonstrated to be effective and has 
been approved for the treatment of metastatic lung cancer 
[6], while only preliminary promising data in patients 
with cervical cancer are available [7]. The identification 
of predictive markers for immunotherapy is evolving. In 
fact, the programmed death-ligand 1 (PD-L1) expression 
in tumor sample is recognized as marker for eligibility to 
immunotherapy in non-small-cell lung cancer (NSCLC) 
although not univocally [8]. Other gene mutations, 
especially those involved in mismatch repair (MMR) may 
predict efficacy of immunotherapy [9]. Here we describe 
the case of a patient with advanced synchronous cancer of 
the cervix and lung where the perspective use of the NGS 
analysis supported the choice of an immunotherapy-based 
treatment with unexpected positive results.
RESULTS
We studied a 48 year-old woman, with a positive 
history of heavy smoking (100 pack/year), with 
synchronous advanced cervical cancer (stage IVA) and 
metastatic NSCLC. The patient oncological history started 
in February 2016 when at another Unit of Obstetrics and 
Gynecology, a locally advanced spinocellular cervical 
cancer has been diagnosed. At that time the magnetic 
resonance imaging (MRI) of the pelvis detected a 
neoplasm that measured 42 × 57 × 64 mm and extended to 
the upper third of the vagina and invaded the parametria 
(cT2B, Nx: Stage IIB). The thorax computed tomography 
(CT) scans also showed a lesion measuring 17 × 7 mm 
localized near the parietal pleura at the superior lobe of 
the left lung and another contralateral lung lesion in the 
right superior lobe. The positron emission tomography 
(PET)/CT confirmed these lesions to be hypermetabolic. 
A CT-guided biopsy of the lung lesion and its histological 
examination revealed primary lung adenocarcinoma 
(Figure 1A). A molecular and biomarker analysis for 
NSCLC indicated the absence of EGFR, ROS, ALK, 
and BRAF mutations. Since the tumors were judged to 
be non-operable, she received 6 cycles of cisplatin plus 
taxol, potentially effective against both tumors. However, 
though the NSCLC was stabilized, in September 2016 
a clear progression of the cervical tumor was seen. 
Following another cycle of chemo-radiotherapy, cervical 
cancer progressed further. Hence, in December 2016 the 
patient was admitted to our Department of Gynecologic 
Oncology, Businco Hospital, Azienda Ospedaliera Brotzu, 
Cagliari. At admission the patient was experiencing strong 
debilitating symptoms such as severe pain [Visual analog 
scale (VAS) 9] in the pelvis and lower back associated 
with heavy spontaneous and malodorous vaginal bleeding 
and discharge. She had abandoned her job and was unable 
to take care of the most common home and personal 
hygiene tasks. Her performance status (PS) was 40 by the 
Karnofsky and 3 by the Eastern Cooperative Oncology 
Group (ECOG) scales. A physical examination showed an 
ulcerative cervical cancer that extended to the lower third 
of the vagina with abundant malodorous leucorrhea and 
easy bleeding. Laboratory analyses showed anemia (Hb 
8.6 g/dl, normal range 12–16 g/dl) and raised indices of 
inflammation (C-reactive protein, CRP, 34 mg/L (normal 
range 0–1 mg/L; Interleukin (IL)-6 158 pg/mL, normal 
range 0–15 pg/ml). An abdominal-pelvic MRI showed 
a cervical neoplasm measuring 42 × 36 × 32 mm that 
extended to the left paracervical side embodying the ureter 
causing hydronephrosis, invaded the posterior wall of the 
bladder and rectum, and extended to the lower third of the 
vagina. Also enlarged confluent lymph nodes measuring 
61 × 23 mm at the left para-aortic level were observed. 
The clinical pre-surgical stage was IVa. The 18F PET/CT 
demonstrated a large area of intense hypercaptation of the 
metabolic tracer in the pelvis and multiple areas in the 
lung (apical segment of the right superior lobe, superior 
segment of the inferior lobe bilaterally, medium postero-
basal segment of the left inferior lobe) and lombo-aortic 
and common iliac lymph nodes (Figure 2A). 
The patient required palliative surgery, and we 
opted for a laparoscopic total pelvic exenteration (LTPE). 
Compared to an open procedure, LTPE is more effective in 
decreasing morbidity, hospital stay, and tumor recurrence, 
and in improving cancer-related survival, quality of life 
(QL) and possibility of starting early other antineoplastic 
treatments. We, therefore, performed LTPE with total 
vaginectomy. The first case of LPTE was performed by 
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Pomel et al. [10] in 2003 to treat a relapse in cervical 
cancer. Since then, the LTPE has been successively 
performed in selected patients at some experienced 
laparoscopic centers [11]. In our case the surgery included 
the excision of the sigma-rectum, bladder, uterus, and 
total vagina as a single mass, extracted via the vaginal 
route, followed by extracorporeal reconstruction by 
cutaneous uretero-ileostomy according to the Bricker 
procedure and fecal diversion by an end-colostomy 
(Supplementary Figure 1). The surgery lasted 400 minutes. 
No intraoperative or perioperative complications occurred. 
No wound hematoma, infection, or delayed bleeding was 
observed postoperatively. The patient was discharged from 
the hospital on postoperative day 5 in good condition. The 
Figure 1: Histological analysis of the lung and cervical cancer. (A) shows histology of non-small-cell-lung cancer adenocarcinoma. 
(B) shows histological findings of the squamous cervical cancer. 
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definitive histological examination (Figure 1B) showed a 
squamous cell carcinoma of the uterine cervix with wide 
necrosis and eso-endocervical ulceration, infiltrating 
the stroma until the serosa, involving the parametria 
bilaterally, extending to 2/3 of the endometrial cavity, and 
deeply infiltrating the bladder and rectum musculature 
without mucosal involvement. 
At this point, considering that the patient was 
heavily pre-treated and showed resistance to standard 
cytotoxic chemotherapy and radiotherapy, in order to 
determine genomic predisposing variants for both tumors 
as well as predictive biomarkers useful to establish a 
rationale targeted approach, we performed simultaneously 
both: a) the analysis of PD-L1 expression both in cervical 
and lung cancer; b) the whole exome NGS of germinal 
DNA (gDNA) from the patient’s peripheral blood. 
Based on the results of PD-L1 assessment and NGS 
that suggested a potential response to immunotherapy, 
we started an immunotherapy regimen with the anti 
PD-1 antibody, nivolumab (3 mg/kg every two weeks). 
Based on the high levels of IL-6 and CRP, both of which 
are potentially immunosuppressive, we also opted for 
a metronomic dose of cyclophosphamide (50 mg/day 
continuously) as an antiblastic and immunomodulating 
agent [12]. Patient received also a supportive therapy for 
specific symptoms control, in detail a combined nutritional 
anticachectic regimen with L-carnitine, lactoferrin, 
aminoacids and antioxidants [13] alongside the appropriate 
analgesic drugs for pain. 
Germline whole exome sequencing analysis
In search of genomic variants mediating 
predisposition and etiology of synchronous cancer 
and mutations predictive of response to treatment, we 
performed NGS of the patient’s germline DNA. The 
whole exome sequencing identified a total of 11344 
genetic variants of which 2388 occurred in non-intronic 
regions (among them 374 missense, 663 3′UTR, 344 
5′UTR, 196 synonymous, 186 splicing, 184 upstream, 
143 downstream, 130 non-frameshift, 56 frameshift, 52 
noncoding RNA, and 10 stop gain variants). 
The analysis was prioritized to identify genetic 
mutations in genes related to cancer predisposition, genes 
involved in DNA repair, genes associated with tobacco 
exposure/nicotine dependence and immune system 
modulation. In particular, variants reported in the general 
population with a minor allele frequency (MAF) lower 
than 1% (MAF<0.01) according to dbSNP database were 
considered.
In detail, the NGS demonstrated 32 genetic variants 
in 25 genes related to DNA repair/cancer predisposition: 
according to dbSNP database we found 16 single 
nucleotide polymorphisms (SNP) (Supplementary 
Table 1). In particular, these included a germline single 
nucleotide variation (SNP: rs61755655) in exon 2 of the 
MLH3 gene (c.408T > C), related to Lynch syndrome and 
a single nucleotide variation (missense variants) (SNP: 
rs140825795) in the exon 1 of the RAD51D gene (c.26G 
> C; p.Cys9Ser), related to a form of hereditary cancer-
predisposing syndrome, according to ClinVar database 
(https://www.ncbi.nlm.nih.gov/clinvar/) (Table 1). These 
genes have been also associated with an increased risk of 
cervical and lung cancer [14–16]. Additional 6 SNPs in 
5 genes involved in nicotine dependence were found, of 
which 3 with a MAF < 0.01 (Table 1 and Supplementary 
Table 1). These included a single missense nucleotide 
variation (SNP: rs56344740) in the exon 6 of the gene 
encoding for the cholinergic receptor nicotinic alpha 
2 subunit (CHRNA2) (c.1434C>A) associated with a 
Table 1: Single nucleotide polimorphysm (SNP) with known clinical significance 
dbSNP Gene ID Locus Reference sequence
Coding DNA 
sequence
Protein 
sequence
MAF
(dbSNP 
database)
Genotype
Clinical 
Significance 
(ClinVar)
Effect PMID
rs61755655 MLH3, mutL homolog 3 chr14:75515951 NM_001040108.1 c.408T>C p.Asp136=
0.0020/10 
(1000 
Genomes)
HET; 
synonimous
Conflicting 
interpretations of 
pathogenicity; Lynch 
syndrome; MLH3-
Related Lynch 
Syndrome
Cancer 
susceptibility 17494052
rs140825795
RAD51D, 
RAD51 
paralog D
chr17:33446607 NM_002878.3 c.26G>C p.Cys9Ser 0.0004/42 (ExAC)
HET; 
missense
Conflicting 
interpretations 
of pathogenicity: 
Breast-ovarian 
cancer, familial 
4, Hereditary 
cancer-predisposing 
syndrome
Cancer 
susceptibility
Cervical cancer
2182226;
24879636;
24139550
rs138463559 MSH6, mutS homolog 6 Chr2: 48030462 NM_000179.2
c.3173-
97T>C
0.0008/4 
(1000 
Genomes)
HET; Intronic Likely benign Colon cancer susceptibility 18523027
rs56344740
CHRNA2, 
cholinergic 
receptor 
nicotinic alpha 
2 subunit
Chr8:27320526 NM_000742.3 c.1434C>A p.Asp478Glu
0.0016/8 
(1000 
Genomes)
HET; 
missense
Benign/Likely 
benign
Nicotine 
dependence/
metabolism
24950454
Results are reported following international guidelines (ref 9). SNPs were matched with dbSNP as population database (http://www.ncbi.nlm.nih.gov/snp) and with ClinVar as disease database (http://www.
ncbi.nlm.nih.gov/clinvar). Abbreviations: Chr, Chromosome; HET, heterozygosis.
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mutation in the third nucleotide of the 478th triplet codon 
(Asp478Glu) that lead to an altered protein function [17]. 
Moreover, 13 SNPs (MAF<0.01 for all) in 
genes reported to be involved in the immune response 
modulation were found (Supplementary Table 1). In 
particular, we observed a splicing variants (rs372373486) 
in the intronic region of the gene encoding for DEAD-
box-helicase 41 (DDX41), a protein involved in the innate 
immune response [18]; an upstream single nucleotide 
variation (rs139470452) in the gene encoding for the 
sialic acid binding Ig like lectin 1, a type I transmembrane 
protein expressed by macrophages and involved in 
mediating cell-cell interactions [19]; a stopgain single 
nucleotide variation (rs148281714) in the gene encoding 
the leukocyte receptor tyrosine kinase, which belongs 
to the ros/insulin receptor family members expressed 
in B lymphocyte progenitors [20]; a splicing variants 
(rs779116887) in the gene encoding for the hepatitis A 
virus cellular receptor 2, a Th1-related protein involved 
in the regulation of macrophage activation, inhibition 
of Th1-mediated immune responses, and promotion of 
immune tolerance [21]; a non-frameshift deletion variants 
(rs773770060) in the exon 5 of the gene encoding for 
the IL-27, a protein that drive expansion and interferon 
gamma production by naïve CD4 T cells [22]; a non-
frameshift deletion variation (rs774578296) of the gene 
encoding for the IL-4 receptor that binds interleukin 4 to 
promote differentiation of Th2 cells [23]; a 3UTR deletion 
variation (rs559799140) in the gene encoding for the 
nuclear factor, erythroid 2 like 2, which is involved in the 
regulation of the myeloid suppressive cells and have been 
correlated with PDL1 expression in lung cancer [24].
PDL1 assessment
The immunohistochemical analysis revealed PDL1 
expression >50% in the lung (immunoreaction intensity 
3+) and about 30% in the cervical tumors (immunoreaction 
intensity 2+).
Patient response to immunotherapy-based 
combination regimen
Five days after surgery, the patient was discharged 
with improved general conditions (PS 2; pain VAS 6). 
Fifteen days after surgery, based on the results of PDL1 
assessment and NGS that suggested a potential response 
to immunotherapy, we started a combination regimen 
with the anti-PD1 antibody nivolumab 3 mg/kg every two 
weeks in combination with metronomic chemotherapy 
(cyclophosphamide 50 mg/day continuously). One month 
after treatment start the patient achieved a significant 
Figure 2: Positron emission tomography (PET) and computed tomography (CT) imaging. The imaging of the disease 
extent before laparoscopic total pelvic exenteratio (Panel A) show in particular in the upper scans a large area of intense hypercaptation 
of the metabolic tracer in the pelvis and in the lombo-aortic and common iliac lymph node (white arrows); in the lower scans multiple 
positive areas in the lung (apical segment of the right superior lobe, superior segment of the inferior lobe bilaterally, a medium postero-
basal segment of the left inferior lobe (white arrows). (Panel B and C) shows the PET/CT and CT imaging before (panel B) and after (panel 
C) chemo-immunotherapy of the: 1-2) left lombo-aortic lymphnodes; 3) right lung nodules; 4-6) left lung nodules; 7) pelvic region.
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improvement in PS (ECOG 1), pain (VAS 0), overall QL, 
and Hb levels associated with a decrease in CRP and IL-6 
levels. The treatment was well tolerated, and no adverse 
effects of any grade were reported by the patient. After 3 
months, the patient resumed working and taking care of 
herself. Evaluation of the tumor objective response by CT 
and PET/CT after 3 and 6 months of combined treatment, 
demonstrated a dimensional and metabolic response at the 
level of the pelvis and the multiple metastatic lung lesions. 
Further PET/CT scans after 9 and 12 months of treatment 
showed a complete response with no evidence of lesions 
with high metabolic activity (Figure 2B–2C). The MRI 
of the pelvis after 12 months of treatment confirmed the 
absence of a neoplastic residual/relapse. Currently, after 
48 cycles of nivolumab, the patient is continuing to benefit 
from treatment: she is in complete remission, has normal 
blood results (Hb 13.5 g/dl), and normal levels of chronic 
inflammatory markers. Her PS is 1, and she is working and 
leading a self-dependent life (Supplementary Figure 1). 
The last CT as well as PET/CT scans confirmed the 
objective and metabolic response.
DISCUSSION
The present report describes a unique case in literature 
of a patient with relapsed synchronous cervical and lung 
cancer who underwent a rationale systemic treatment, 
including the most modern antineoplastic approach, based 
on the use of perspective NGS with an unexpected positive 
response both in terms of survival and QL. 
Indeed, in literature the description of exceptional 
responders, i.e. patients who achieve an extraordinary 
response to treatments, “are emerging as frontrunner 
cases for NGS analysis” and represent a relevant source 
for the discovery of novel genomic alterations predictive 
for specific tailored approaches [25].
Notably, in our case the patient was firstly treated 
with optimal palliative laparoscopic surgery; thus, we 
affirm how LTPE when performed in selected patients 
with cervical cancer can have a significant role in opening 
the road to other life-prolonging antineoplastic treatments 
[26], allowing also their early start [27]. Thus, tumor 
exenteration which was once considered only for the 
purpose of palliation without increasing the life expectancy 
is not only capable of improving the patient general well-
being but can give also the time to allows the use of 
further innovative therapeutic strategies. Moreover, even 
if severe symptoms able to interfere with the physical, 
psychological, emotional well-being of the patient were 
sufficient to decide for a palliative surgery, the presence of 
concomitant synchronous neoplasms made such surgical 
approach mandatory. In fact, in this case palliation of one 
tumor’s symptoms could help in the treatment of the other 
tumor, which can potentially benefit from effective and 
specific systemic drugs. Therefore, although symptoms 
relief, reported in 67–90% of patients [28], and not just 
survival, is the best measure of success after palliative 
exenteration, a substantial improvement in the QL 
associated with life prolongation cannot be excluded when 
other interdisciplinary treatments are introduced. Here, 
we confirm the success of this interdisciplinary approach, 
which depends on the shared skills of the operating teams 
and the harmony between them. 
Consistently, in our case immediately after having 
obtained a significant improvement of the patient general 
well-being with surgery, we performed a perspective NGS 
analysis of the germinal whole exome in order to find 
predisposing genetic factors for the synchronous cancers 
and even more genetic variants of predictive parameters 
useful to choose the best and most effective therapeutic 
strategy. Indeed, since the patient was heavily pre-treated 
and progressed under standard cytotoxic agents both 
for cervical and lung cancer, the choice of an effective 
treatment was challenging and complex. Then, considering 
that anti-PD1 antibodies are approved for the treatment 
of NSCLC [6] and showed preliminary positive results 
in cervical cancer [7], we searched with NGS genetic 
variants that may be predictive of immunotherapy efficacy. 
Additionally, being already known that in NSCLC the 
tumor expression of PD-L1 represents a parameter for 
eligibility to such drugs, we have assessed it also in the 
cervical tumor sample and we found a hyperexpression in 
both cancers (>50% in NSCLC sample and about 30% in 
cervical cancer). 
NGS analysis revealed both the presence of some 
significant gene variants known to predispose to lung 
and cervical cancers as well as to nicotine dependence 
and chronic lung diseases thus hypothesizing a common 
etiology and then a possible common therapeutic 
strategy, and notably also demonstrated genetic variants 
predictive of response to immunotherapy, thus supporting 
strongly our treatment choice. In particular, we identified 
some germline mutations in several genes involved in 
mismatch repair (MMR), which have been associated 
with increased efficacy of immunotherapy [9]. Mutations 
in MMR genes impair DNA repair, which can lead to 
microsatellite instability (MSI). MSI, which is believed 
also to be a predictor of chemoresistance [9] as we 
observed in our patient, is associated with high frequencies 
of non-synonymous and frameshift mutations that result 
in increased neo-antigen formation. Neoantigens are 
recognized as foreign by the immune system and induce 
a stronger, longer, and more specific immune response 
against the tumor. Some authors have shown that mutations 
in DNA repair and replication genes are associated with 
a higher mutational load and correlated with increased 
response to the PD-1 blockade [29–31]. Based on this 
evidence, very recently the FDA recognized MSI as a 
predictor of sensitivity for immunotherapy approaches. 
Additionally, the genomic analysis in our case also 
identified significant SNPs in DEAD-box-helicase 41, a 
protein involved in the innate immune response, which 
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is related to Interferon signaling [32], and other genes for 
cytokines, chemokine receptors, and other factors, such as 
the the sialic acid binding Ig like lectin 1, the hepatitis A 
virus cellular receptor 2 and the nuclear factor erythroid 2 
like 2, that are involved in macrophage activation whose 
roles in modulating the response to immunotherapy has 
already been hypothesized in literature [33–35].
On the basis of all the above findings, we provide 
a strong molecular and genetic rationale for the choice of 
a treatment protocol which consisted of immunotherapy 
with antiPD1 antibody also for our patient affected by 
chemoresistant advanced cervix cancer and synchronous 
NSCLC, after palliative laparoscopic surgery for the 
cervical cancer relapse. We combined the immune 
checkpoint inhibitor nivolumab with metronomic 
cyclophosphamide. Such choice was based on the evidence 
that our patient presented a cancer-related severe chronic 
inflammation, which is able to impair the specific immune 
response mediated by T cell [12]. In fact, metronomic 
chemotherapy and in particular cyclophosphamide 
showed anti-inflammatory and immunomodulating 
actions that determine a synergism with immunotherapy 
[12]. In particular, cyclophosphamide is capable to 
modulate the tumor microenvironment by inhibiting 
the immunosuppressive macrophagic activity and the 
synthesis of proinflammatory mediators (prostaglandin 
and cytokines) [36]. As result of our therapeutic approach, 
and after 48 administrations of nivolumab, the patient has 
a complete objective and metabolic response, and she is 
surviving with a good PS and a marked improvement in QL, 
for more than 24 months after the LTPE was performed. At 
this regard it should also be noted that our patient passed 
the median duration of response observed in the largest 
trials on the treatment with anti PD1 antibody in patients 
with NSCLC adenocarcinoma [6] and, more significantly, 
the median duration of progression-free survival reported 
cervical cancer patients treated with pembrolizumab in one 
clinical trial [7] and few case series [37, 38]. 
In conclusion, the present case strongly affirms 
the need for an interdisciplinary approach by combining 
surgical and medical strategies and supports the use of 
NGS to drive a targeted rational treatment in heavily pre-
treated patients with cervical cancer synchronous to lung 
cancer. 
Future perspective larger research with 
implementation of both germinal and somatic genomic 
sequencing are warranted to expand the development of 
new targeted immunotherapy-based approaches, as those 
described in the present paper.
MATERIALS AND METHODS
Oversight
The study protocol was approved by the local 
institutional review board and conducted according to 
the principles expressed in the Declaration of Helsinki. 
The patient provided written informed consent for the 
treatment protocol and also for genomic analysis as well as 
for the case report and accompanying images publication. 
Germline whole exome sequencing analysis 
Whole exome NGS of the germinal DNA obtained 
from patient’s peripheral blood cells was performed 
using the Illumina HiSeq NGS platform that can detect 
mutations (single nucleotide polymorphism) and copy-
number variations. We focused on genes related to cancer 
predisposition, DNA repair, tobacco exposure /nicotine 
dependence as well as on genetic variants of parameters 
that could be predictive of response to targeted/
immunological strategies potentially useful in our patient 
who showed to be resistant to conventional chemotherapy. 
We focused on rare variants, with MAF < 0.01, which 
can exert a central role in the generation of complex 
traits and be responsible of heritability not explained by 
common variants. Results of NGS are reported following 
international guidelines [39].
PDL1 assessment
We assessed the expression of PDL1 in 
specimens of primary lung and cervical cancers, by 
immunohistochemistry. 
Surgical technique
Details of the procedure are reported in the 
Supplementary Appendix. 
Clinical, laboratory and quality of life outcomes
The patient’s tumor objective response was 
monitored as per the iRECIST criteria [40]. It was 
evaluated every 4–6 months by pelvic MRI, CT and 
PET/CT. Toxicity was evaluated by the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events, version 4.03. In addition to the routine laboratory 
analyses, we also evaluated changes in circulating levels 
of the proinflammatory cytokine IL-6 (by enzyme-linked 
immune assay) and CRP. We also determined PS, pain 
(VAS) and QL by the European Organization for Research 
and Treatment of Cancer quality of life Questionnaire 
(EORTC-QLQ)-C30. All assessments were made every 
month. 
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NGS: next generation sequencing; PD: programmed 
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